Seroprevalence of hepatitis C in haemodialysis patients in tertiary care hospital in Punjab

Jaspal Kaur, Loveena Oberoi, Kanwardeep Singh, Rakesh Chander


Background: Hepatitis C is an emerging infectious disease all over the world especially in the developing countries. HCV is a blood borne virus, well known risk factors include blood transfusion, injection drug abuse, chronic haemodialysis patients. HCV is a single stranded positive sense RNA virus, belongs to family flaviviridae and genus Hepacivirus. Haemodialysis patients are the high risk group due to prolonged vascular access and contaminated equipments.

Methods: The present study was retrospective conducted from June 2019 to 31 July 2020 in the Department of Microbiology, Government Medical College, Amritsar. Clinical, demographic and geographical data of the renal disease patients admitted to the hospital for haemodialysis was recorded and analysed. The patients were tested for HCV by Third Generation ELISA.

Results: In the present study, out of enrolled 186 patients, 12 were HCV positive (0.06%). Prevalence of Hepatitis C infection in haemodialysis patients is   associated with gender distribution more in females (72%) than males (62%), preponderance of HCV infection was observed in age group 41-60 years (69%) followed by 21-40 years (23%),more rural (85%) distribution. Diabetes (19%), hypertension (25%) and chronic kidney disease (63%) were the associated comorbid conditions.

Conclusions: The overall HCV sero prevalence was observed to be 0.06%, this low prevalence can be attributed to the fact that increased awareness regarding the disinfection of dialysis machines by improving the surveillance system of HCV and better education of nurses in dialysis units. HD patients should be routinely screened for HCV infection.


Hepatitis C, Hemodialysis, Seroprevalence

Full Text:



Khaja MN, Munpally SK, Hussain MM, Habeebullah CM. Hepatitis C virus: the Indian scenario. Current Science Bangalore. 2002;83(3):219-24.

Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clinical infectious diseases. 2012;55(suppl_1):S10-5.

Bhaumik P, Debnath K. Prevalence of hepatitis B and C among haemodialysis patients of Tripura, India. Euroasian J Hepato-Gastroenterol. 2012;2(1):10-3.

Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. The Lancet infectious diseases. 2002;2(5):293-302.

Lemon SM, Walker CM, Alter MJ, Yi M. Hepatitis C Virus. In: Knipe DM, Howley PM (eds.), Fields Virology, Volume 1, Lippincott Williams & Wilkins, Philadelphia; 2007: 1253-1304.

Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. The Lancet. 2000;355(9207):887-91.

Naik SA, Banashankari GS, Beena GD, Sreeja S. Prevalence of Hepatitis C Infection In A Tertiary Care Hospital In South India. Natl Jouranal Lab Med. 2012;1(1):20-7.

Chadha MS, Tungatkar SP, Arankalle VA. Insignificant prevalence of antibodies to hepatitis C in a rural area of western Maharashtra. Indian Journal of Gastroenterology: official Journal of the Indian Society of Gastroenterology. 1999;18(1):22-3.

Chandra M, Khaja MN, Farees N, Poduri CD, Hussain MM, Habibullah CM. Prevalence, risk factors and genotype distribution of HCV and HBV infection in the tribal population: a community based study in south India. Tropical gastroenterology: official journal of the Digestive Diseases Foundation. 2003;24(4):193-5.

Chowdhury A, Santra A, Chaudhuri S, Dhali GK, Chaudhuri S, Maity SG, Naik TN, Bhattacharya SK, Mazumder DN. Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. Hepatology. 2003;37(4):802-9.

Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV. Transfusion-associated hepatitis not due to viral hepatitis type A or B. New England Journal of Medicine. 1975;292(15):767-70.

Prince A, Grady G, Hazzi C, Brotman B, Kuhns W, Levine R, Millian S. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. The Lancet. 1974;304(7875):241-6.

Arankalle VA, Chadha MS, Jha J, Banerjee K, Hepatitis C virus infection in patients with end stage renal disease. 2015;6(1):21-5.

Arankalle VA, Chadha MS, Jha J, Banerjee K. Hepatitis C virus infection in patients with end stage renal disease. 2015;6(1):21-5.

Gosavi MS, Shah SK, Shah SR, Pal RB, Saldanha JA, Banker DD. Indian J Med Sci. 1997;51(10):378-85. irus. Lancet.1974;2:241-6.

Chandra M, Khaja MN, Hussain MM, Poduri CD, Farees N, Habeeb MA, et al. Prevalence of Hepatitis B and Hepatitis CViral Infections in Indian Patients with Chronic Renal Failure. Intervirology. 2004;47(6):374-6.

Agarwal SK, Dash SC, Irshad M, Hepatitis C virus infection during haemodialysis in India, PubMed, J Assoc Physicians India. 1999;47(12):1139-4316.

Hinrichsen H, Leimenstoll G, Stegen G, Schrader H, Fölsch UR, Schmidt WE. Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients. Gut. 2002;51(3):429-33.

Couroucé AM, MARREC NL, Girault A, Ducamp S, Simon N. Anti‐hepatitis C virus (anti‐HCV) seroconversion in patients undergoing hemodialysis: comparison of second‐and third‐generation anti‐HCV assays. Transfusion. 1994;34(9):790-5.

Lakshmi V, Reddy AK, Dakshinamurty KV. Brief Communication-Evaluation of commercially available third-generation anti-hepatitis C virus enzyme-linked immunosorbent assay in patients on haemodialysis. Indian Journal of Medical Microbiology. 2007;25(2):140-2.

Lee SR, Peterson J, Niven P, Bahl C, Page E, DeLeys R, et al. Efficacy of a hepatitis C virus core antigen enzyme‐linked immunosorbent assay for the identification of ‘window‐phase’blood donations. Vox sanguinis. 2001;80(1):19-23.

Jadoul M. Epidemiology and mechanisms of transmission of the hepatitis C virus in haemodialysis. Nephrology Dialysis Transplantation. 2000;15(90008):39-41.

Taskapan HÜ, Oymak O, Dogukan A, Utas C. Patient to patient transmission of hepatitis C virus in hemodialysis units. Clinical nephrology. 2001;55(6):477-81.

CDC Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morbidity Mortality Weekly Rep. 1998;47:1-39.